ERBB2 and breast cancer: The data in this trial were consistent with guidelines from the Choosing Wisely campaign of the Society of Surgical Oncology,19 which recommends omitting SLNB in patients older than 70 years with small ER-positive ERBB2-negative BC when the adjuvant treatment plan is clear and does not include the addition of chemotherapy to endocrine treatment.